Green Ariel R, Segal Jodi, Boyd Cynthia M, Huang Jin, Roth David L
Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Mason F. Lord Building, Center Tower, 5200 Eastern Ave., 7th Floor, Baltimore, MD, 21224, USA.
Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Drugs Real World Outcomes. 2020 Jun;7(2):151-159. doi: 10.1007/s40801-020-00181-z.
Emergency department (ED) visits or hospitalizations should prompt review of the patient's medications after discharge and targeted deprescribing to reduce ongoing risks.
To see if this is happening, we sought to examine the proportion of serious falls and delirium that were followed by a prescription fill for a bladder antimuscarinic. Our secondary objective was to identify concurrent use of other anticholinergics, cholinesterase inhibitors (ChEIs), and diuretics among people with dementia taking bladder antimuscarinics.
Retrospective descriptive study using data from the National Health and Aging Trends Study (2011-2014) linked with Medicare claims from 2010-2014. The primary outcome was the proportion of serious falls or delirium that were followed by a bladder antimuscarinic prescription fill within 12 months. The secondary outcome was the proportion of individuals concurrently receiving prescriptions for bladder antimuscarinics, other strong anticholinergics, ChEIs, and diuretics.
During the observation period, 8.88% of people with dementia filled a bladder antimuscarinic prescription. Over one-third (35%) initiated use after being identified as having dementia. Many used bladder antimuscarinics concurrently with other strong anticholinergics (19%), diuretics (42%), and ChEIs (32%). The majority (76%) of serious falls or delirium among people with dementia and bladder antimuscarinic use were followed by a bladder antimuscarinic prescription within 12 months.
In this descriptive study, bladder antimuscarinic prescriptions were often filled irrespective of dementia status, serious falls, or delirium. Concurrent use of other anticholinergics, diuretics, and ChEIs was common. Falls and delirium should trigger review of the medication list after discharge and targeted deprescribing in people with dementia.
急诊科就诊或住院后应促使对患者出院后的用药情况进行复查,并进行有针对性的减药以降低持续存在的风险。
为了解这种情况是否存在,我们试图研究严重跌倒和谵妄后开具膀胱抗毒蕈碱药物处方的比例。我们的次要目的是确定服用膀胱抗毒蕈碱药物的痴呆患者中同时使用其他抗胆碱能药物、胆碱酯酶抑制剂(ChEIs)和利尿剂的情况。
采用回顾性描述性研究,使用来自国家健康与老龄化趋势研究(2011 - 2014年)的数据,并与2010 - 2014年的医疗保险理赔数据相链接。主要结局是严重跌倒或谵妄后12个月内开具膀胱抗毒蕈碱药物处方的比例。次要结局是同时接受膀胱抗毒蕈碱药物、其他强效抗胆碱能药物、ChEIs和利尿剂处方的个体比例。
在观察期内,8.88%的痴呆患者开具了膀胱抗毒蕈碱药物处方。超过三分之一(35%)在被确诊为痴呆后开始使用。许多人同时将膀胱抗毒蕈碱药物与其他强效抗胆碱能药物(19%)、利尿剂(42%)和ChEIs(32%)合用。痴呆且使用膀胱抗毒蕈碱药物的患者中,大多数(76%)在严重跌倒或谵妄后12个月内开具了膀胱抗毒蕈碱药物处方。
在这项描述性研究中,无论痴呆状态、严重跌倒或谵妄情况如何,膀胱抗毒蕈碱药物处方经常被开具。同时使用其他抗胆碱能药物、利尿剂和ChEIs的情况很常见。跌倒和谵妄应促使在出院后复查用药清单,并对痴呆患者进行有针对性的减药。